{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:04:19Z","timestamp":1791180259322,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2012,10,5]],"date-time":"2012-10-05T00:00:00Z","timestamp":1349395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>B cell activating factor (BAFF) plays a crucial role in the process of development, maturation and activation of B lymphocytes. Chronic hepatitis C virus (HCV) infection is characterized by multiple B cell disorders. It is a major cause of type II mixed cryoglobulinaemia (MC). We measured serum BAFF levels in several clinical situations to elucidate the potential role of BAFF in chronic HCV infection. We used a commercially available solid phase enzyme-linked immunosorbent assay. We estimated serum BAFF in stored sera from uninfected controls (n = 8), patients with chronic hepatitis B virus infection HBV (n = 5) and chronic HCV infection with (n = 16) and without mixed cryoglobulinaemia (n = 14). In two patients with HCV and MC we correlated BAFF with HCV RNA after pegylated interferon (peg-I). We correlated serum BAFF levels at baseline and at 12 weeks with treatment response: sustained virological response SVR (n = 5), non-responders (n = 6) and relapsers (n = 2). Finally, we estimated BAFF levels after complete depletion of B cells with rituximab in patients with chronic HCV with MC (n = 3). Serum levels of BAFF were increased in chronic HCV with MC, but not in chronic HBV infection, suggesting an association between BAFF and cryoglobulinaemia. Peg-I increased BAFF levels in serum and this paralleled HCV RNA very closely. Serum BAFF levels at week 12 of therapy with peg-I and R were significantly higher in responders than non-responders. Finally, B cell depletion was associated with markedly increased levels of BAFF.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2012.04653.x","type":"journal-article","created":{"date-parts":[[2012,8,20]],"date-time":"2012-08-20T12:11:09Z","timestamp":1345464669000},"page":"231-237","source":"Crossref","is-referenced-by-count":23,"title":["B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia"],"prefix":"10.1093","volume":"170","author":[{"given":"G","family":"Lake-Bakaar","sequence":"first","affiliation":[{"name":"Center for the Study of Hepatitis C, Weill Medical College Cornell University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Center for the Study of Hepatitis C, Weill Medical College Cornell University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Talal","sequence":"additional","affiliation":[{"name":"Center for the Study of Hepatitis C, Weill Medical College Cornell University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,10,5]]},"reference":[{"key":"2021122708262579300_cei4653-bib-0001","first-page":"137","article-title":"B cell activating factor, its role in autoimmunity, and targeting in autoimmune diseases","volume":"110","author":"Krivosikova","year":"2009","journal-title":"Bratisl Lek Listy"},{"key":"2021122708262579300_cei4653-bib-0002","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1074-7613(04)00079-2","article-title":"Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF","volume":"20","author":"Lesley","year":"2004","journal-title":"Immunity"},{"key":"2021122708262579300_cei4653-bib-0003","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"2021122708262579300_cei4653-bib-0004","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.4049\/jimmunol.174.9.5537","article-title":"BAFF augments certain Th1-associated inflammatory responses","volume":"174","author":"Sutherland","year":"2005","journal-title":"J Immunol"},{"key":"2021122708262579300_cei4653-bib-0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/rheumatology\/kel177","article-title":"Virus-associated B-cell proliferation \u2013 the role of serum B lymphocyte stimulator (BLyS\/BAFF)","volume":"46","author":"Sene","year":"2007","journal-title":"Rheumatology (Oxf)"},{"key":"2021122708262579300_cei4653-bib-0006","first-page":"S78","article-title":"HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies","volume":"21","author":"Ferri","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"2021122708262579300_cei4653-bib-0007","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/1529-0131(200001)43:1<94::AID-ANR12>3.0.CO;2-8","article-title":"Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma","volume":"43","author":"De Vita","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2021122708262579300_cei4653-bib-0008","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/sarh.2002.33724","article-title":"Th1\/Th2 cytokine imbalance in patients with Sjogren syndrome secondary to hepatitis C virus infection","volume":"32","author":"Ramos-Casals","year":"2002","journal-title":"Semin Arthritis Rheum"},{"key":"2021122708262579300_cei4653-bib-0009","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021122708262579300_cei4653-bib-0010","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/art.30274","article-title":"Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors","volume":"63","author":"Gragnani","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021122708262579300_cei4653-bib-0011","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2008-07-170613","article-title":"Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia?","volume":"112","author":"Giannini","year":"2008","journal-title":"Blood"},{"key":"2021122708262579300_cei4653-bib-0012","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2021122708262579300_cei4653-bib-0013","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","article-title":"A role for hepatitis C virus infection in type II cryoglobulinemia","volume":"327","author":"Agnello","year":"1992","journal-title":"N Engl J Med"},{"key":"2021122708262579300_cei4653-bib-0014","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2000-9613","article-title":"The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and overt B-cell malignancy","volume":"20","author":"Dammacco","year":"2000","journal-title":"Semin Liver Dis"},{"key":"2021122708262579300_cei4653-bib-0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaut.2006.07.005","article-title":"Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity","volume":"27","author":"Toubi","year":"2006","journal-title":"J Autoimmun"},{"key":"2021122708262579300_cei4653-bib-0016","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.micpath.2009.12.002","article-title":"Serum cytokine profile in hepatitis C virus carriers presenting cryoglobulinaemia and non-organ-specific autoantibodies","volume":"48","author":"Atta","year":"2010","journal-title":"Microb Pathog"},{"key":"2021122708262579300_cei4653-bib-0017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"2021122708262579300_cei4653-bib-0018","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","article-title":"Viral dynamics in hepatitis B virus infection","volume":"93","author":"Nowak","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122708262579300_cei4653-bib-0019","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2893.2007.00938.x","article-title":"Substitution rate of the hepatitis B virus surface gene","volume":"15","author":"Zaaijer","year":"2008","journal-title":"J Viral Hepat"},{"key":"2021122708262579300_cei4653-bib-0020","doi-asserted-by":"crossref","first-page":"e1000565","DOI":"10.1371\/journal.pcbi.1000565","article-title":"The evolutionary dynamics of a rapidly mutating virus within and between hosts: the case of hepatitis C virus","volume":"5","author":"Luciani","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"2021122708262579300_cei4653-bib-0021","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1073\/pnas.88.8.3392","article-title":"Nucleotide sequence and mutation rate of the H strain of hepatitis C virus","volume":"88","author":"Ogata","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122708262579300_cei4653-bib-0022","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2005.02.7938","article-title":"Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders","volume":"24","author":"Novak","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122708262579300_cei4653-bib-0023","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1158\/0008-5472.CAN-08-4915","article-title":"Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma","volume":"69","author":"Novak","year":"2009","journal-title":"Cancer Res"},{"key":"2021122708262579300_cei4653-bib-0024","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.gene.6363923","article-title":"Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis","volume":"3","author":"Kawasaki","year":"2002","journal-title":"Genes Immun"},{"key":"2021122708262579300_cei4653-bib-0025","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/ar1912","article-title":"B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome","volume":"8","author":"Ittah","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2021122708262579300_cei4653-bib-0026","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/eji.200738013","article-title":"Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways","volume":"38","author":"Ittah","year":"2008","journal-title":"Eur J Immunol"},{"key":"2021122708262579300_cei4653-bib-0027","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000321194","article-title":"Induction of B cell-activating factor by viral infection is a general phenomenon, but the types of viruses and mechanisms depend on cell type","volume":"3","author":"Ittah","year":"2010","journal-title":"J Innate Immun"},{"key":"2021122708262579300_cei4653-bib-0028","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/art.23515","article-title":"Direct B cell stimulation by dendritic cells in a mouse model of lupus","volume":"58","author":"Wan","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021122708262579300_cei4653-bib-0029","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.20041674","article-title":"BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma","volume":"201","author":"Krumbholz","year":"2005","journal-title":"J Exp Med"},{"key":"2021122708262579300_cei4653-bib-0030","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1089\/jir.2008.0007","article-title":"BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis","volume":"28","author":"Gandhi","year":"2008","journal-title":"J Interferon Cytokine Res"},{"key":"2021122708262579300_cei4653-bib-0031","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/1352458510393771","article-title":"Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production","volume":"17","author":"Hedegaard","year":"2010","journal-title":"Mult Scler"},{"key":"2021122708262579300_cei4653-bib-0032","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s15010-007-6299-1","article-title":"Cryoglobulinemia-related vasculitis during effective anti-HCV treatment with PEG-interferon alfa-2b","volume":"36","author":"De Blasi","year":"2008","journal-title":"Infection"},{"key":"2021122708262579300_cei4653-bib-0033","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10067-005-1093-x","article-title":"Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature","volume":"24","author":"Beuthien","year":"2005","journal-title":"Clin Rheumatol"},{"key":"2021122708262579300_cei4653-bib-0034","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.meg.0000108342.41221.0c","article-title":"Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa","volume":"16","author":"Batisse","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2021122708262579300_cei4653-bib-0035","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","article-title":"Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study","volume":"116","author":"Dammacco","year":"2010","journal-title":"Blood"},{"key":"2021122708262579300_cei4653-bib-0036","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2893.2009.01093.x","article-title":"Serum BLyS\/BAFF predicts the outcome of acute hepatitis C virus infection","volume":"16","author":"Tarantino","year":"2009","journal-title":"J Viral Hepat"},{"key":"2021122708262579300_cei4653-bib-0037","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122708262579300_cei4653-bib-0038","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021122708262579300_cei4653-bib-0039","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2021122708262579300_cei4653-bib-0040","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/TP.0b013e3181bbba1a","article-title":"BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection","volume":"88","author":"Zarkhin","year":"2009","journal-title":"Transplantation"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2012.04653.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/170\/2\/231\/41907252\/cei4653.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/170\/2\/231\/41907252\/cei4653.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:24:12Z","timestamp":1641054252000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/170\/2\/231\/6429044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,5]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,10,5]]},"published-print":{"date-parts":[[2012,10,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2012.04653.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,11]]},"published":{"date-parts":[[2012,10,5]]}}}